A study to investigate vepoloxamer (Carmeseal-MD) for Duchenne muscular dystrophy

Trial Profile

A study to investigate vepoloxamer (Carmeseal-MD) for Duchenne muscular dystrophy

Planning
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Poloxamer 188 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Sep 2016 According to a Phrixus Pharmaceuticals media release, the US FDA allowed IND application for poloxamer-188 in DMD.
    • 19 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top